3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDIV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Retroperitoneal liposarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Melanoma
1
Liposarcoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Chondrosarcoma
1
Interventions
Doxorubicin
3
spartalizumab
1
nilotinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
envafolimab
1
Trabectedin
1
TQ-B3525
1
Radiotherapy
1
Proton Therapy
1
Nivolumab
1
Neoadjuvant Therapy
1
Ipilimumab
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Heavy Ion Radiotherapy
1
Gelclair
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Chondrosarcoma
×
nilotinib
×
Clear all
NCT02587169
2015-10-27
GEIS-27
Broto, Javier MartÃn, M.D.
Phase 1/2
Unknown
40 enrolled